Weigh Risks Versus Benefits in Cancer Patients Needing an Anticoagulant
February 2019
You'll see clarity about which anticoagulant to use in patients with cancer-associated thromboembolism...due to new Canadian expert guidance.
Dalteparin (Fragmin) and other low-molecular-weight heparins (LMWH) are usually preferred to treat and prevent recurrent venous thromboembolism (VTE) in patients with cancer.
Now more evidence suggests that direct oral anticoagulants (DOACs), such as rivaroxaban (Xarelto), work about as well as LMWH at lowering recurrent VTE risk in cancer patients. Plus DOACs are oral...and cost up to $150/month versus up to $1,800/month for LMWH.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive